natgillin/translations-raw huggingface dataset:
Apply the content of the pipette to a single spot on the skin of the cat’s neck at the base of the skull.
Nanesite vsebino merilne kapalke na eno mesto kože vratu na zatilje glave mačke.
Apply the content of the pipette to a single spot on the skin of the cat’s neck at the base of the skull.
Nanesite vsebino merilne kapalke na eno mesto kože vratu na zatilju glave mačke.
Apply the content of the pipette to a single spot on the skin of the dog at the base of the skull.
Razprite dlako in nanesite vsebino pipete na eno mesto kože vratu na zatilju glave psa.
Apply the dose to an area where your dog cannot lick it off and do not allow your dog or other animals lick each other following treatment.
Pomembno je, da nanesemo zdravilo na mesto, kjer ga pes ne bo mogel polizati, in da zagotovimo, da tudi druge živali po zdravljenju ne ližejo druga druge.
Apply the next dose as soon as possible.
Nanesite naslednji odmerek takoj, ko je mogoče.
Apply the patch immediately after removing it from the sachet.
Namestite ga takoj, ko ga vzamete iz zaščitne vrečice.
Apply the product into the ear canal by pressing it between two fingers.
Zdravilo aplicirajte v sluhovod tako, da ga stisnete med prstoma.
Apply the veterinary medicinal product (as directed in step 4 below) slowly with the tip of the applicator on the skin.
Nanesite zdravilo (kot je navedeno v koraku 4 spodaj) počasi s konico kapalke na koži.
Apply the veterinary medicinal product slowly with the tip of the applicator on the skin.
Nanesite zdravilo počasi s konico aplikatorja na koži.
Apply this medicine to the affected area once a day just before bedtime.
To zdravilo nanesite na prizadeti predel enkrat na dan tik pred spanjem.
Apply to the skin at the base of the neck in front of the shoulder blades.
Razmaknemo dlako v predelu zatilja (pred lopaticami), da se pokaže nekoliko kože.
Apply topically to the skin at the base of the skull.
Nanesite lokalno na kožo na spodnjem delu lobanje.
Apply usual aseptic procedures.
Poslužujte se ukrepov za izvajanje asepse.
Apply usual procedures for the handling of animals.
Potrebni so ukrepi, ki se običajno izvajajo pri ravnanju z živalmi.
Apply your first patch during the first 24 hours of your period
Prvi obliž namestite v prvih 24 urah menstruacijskega cikla.
Applying Kentera while taking other medicines that have similar side effects, such as dry mouth, constipation, and drowsiness, may increase how often and how severe these side effects are experienced.
Sočasna uporaba zdravila Kentera in drugih zdravil, ki imajo podobne neželene učinke, kot so suha usta, zaprtje in dremavost, lahko poveča njihovo pogostnost in resnost.
Applying the Kentera patch at the same time as taking other medicines that have similar side effects such as dry mouth, constipation and drowsiness, may increase how often and how severe these side effects are experienced.
Sočasna namestitev obliža Kentera in uporaba drugih zdravil, ki imajo podobne neželene učinke, kot so suha usta, zaprtje in dremavost, lahko zvečata pogostnost in resnost teh neželenih učinkov.
approach is a dose titration of the
antidepresiva na podlagi klinične
Appropriate
lopinavir/ritonavir
Appropriate adjustment of dose and dose intervals should be made in order to maintain haemoglobin values at the desired level: haemoglobin between 10 g/dl and 12 g/dl (6.2 to 7.5 mmol/l).
Potrebno je ustrezno prilagoditi odmerek in intervale odmerjanja za vzdrževanje vrednosti hemoglobina na želeni ravni: hemoglobin med 10 g/dl in 12 g/dl (med 6,2 in 7,5 mmol/l).
Appropriate adjustment of the dose should be made in order to maintain haemoglobin concentrations within the desired concentration range between 10 g/dl to 12 g/dl (6.2 to 7.5 mmol/l).
Treba je ustrezno prilagoditi odmerek za vzdrževanje koncentracij hemoglobina v želenem razponu koncentracije med 10 g/dl in 12 g/dl (med 6,2 in 7,5 mmol/l).
Appropriate adjustment of the dose should be made in order to maintain haemoglobin levels within the desired concentration range between 9.5 g/dl to 11 g/dl (5.9 to 6.8 mmol/l).
Treba je ustrezno prilagoditi odmerek za vzdrževanje ravni hemoglobina v želenem razponu koncentracije med 9,5 g/dl in 11 g/dl (med 5,9 in 6,8 mmol/l).
Appropriate adjustment of the dose should be made in order to maintain haemoglobin values at the desired level between 10 g/dl to 12 g/dl (6.2 to 7.5 mmol/l).
Potrebno je ustrezno prilagoditi odmerek za vzdrževanje vrednosti hemoglobina v želeni ravni med 10 g/dl in 12 g/dl (med 6,2 in 7,5 mmol/l).
Appropriate adjustment of the dose should be made in order to maintain haemoglobin values within the desired concentration range between 10 g/dl to 12 g/dl (6.2 to 7.5 mmol/l).
Potrebno je ustrezno prilagoditi odmerek za vzdrževanje vrednosti hemoglobina v želenem razponu koncentracije med 10 g/dl in 12 g/dl (med 6,2 in 7,5 mmol/l).
Appropriate adjustment of the dose should be made in order to maintain haemoglobin values within the desired concentration range between 10 g/dl to 12 g/dl (6.2 to 7.5 mmol/l).
Treba je ustrezno prilagoditi odmerek za vzdrževanje vrednosti hemoglobina v želenem razponu koncentracije med 10 g/dl in 12 g/dl (med 6,2 in 7,5 mmol/l).
Appropriate adjustment of the immunosuppression regimen should be considered in patients with elevated serum creatinine levels.
Ustrezno prilagajanje imunosupresijske sheme naj pride v poštev pri bolnikih z zvišanimi koncentracijami serumskega kreatinina.
Appropriate administration materials must be composed of glass, polyolefin, or polyethylene to avoid excessive loss of medicinal product and to decrease the rate of DEHP extraction.
Materiali, primerni za dajanje zdravila, morajo biti sestavljeni iz stekla, poliolefina ali polietilena, s čimer se izognemo večjim izgubam zdravila in zmanjšamo hitrost ekstrakcije DEHP.
Appropriate anti- infective therapy should be started immediately and discontinuation of therapy should be considered.
Potrebno je takoj pričeti z ustreznim zdravljenjem proti okužbam in razmisliti o prekinitvi zdravljenja.
Appropriate aseptic technique should be used when preparing the infusion.
Pri pripravi infuzije je treba uporabiti aseptično tehniko.
Appropriate assessment of renal function is recommended prior to initiation of Vipdomet and at regular intervals thereafter (see section 4.4).
Pred uvedbo zdravljenja z zdravilom Vipdomet in v rednih časovnih presledkih med zdravljenjem priporočamo izvedbo ustreznih preiskav za oceno delovanja ledvic (glejte poglavje 4.4).
Appropriate bronchodilator therapy and resuscitative measures should be available prior to Rapiscan administration.
Pred dajanjem zdravila Rapiscan je treba zagotoviti, da so na voljo ustrezno zdravljenje z bronhodilatatorji in ukrepi za oživljanje srca.
Appropriate care is advised when prescribing TREVICTA to patients who will be experiencing conditions which may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medicinal products with anticholinergic activity or being subject to dehydration.
Pri predpisovanju zdravila TREVICTA bolnikom, ki se lahko znajdejo v okoliščinah, ko se zviša temperatura jedra, npr. naporna telesna vadba, izpostavljenost skrajni vročini, sočasno jemanje zdravil z antiholinergičnim delovanjem ali dehidracija, svetujemo ustrezno oskrbo.
Appropriate care is advised when prescribing Xeplion to patients who will be experiencing conditions which may contribute to an elevation in core body temperature, e.g. exercising strenuously, exposure to extreme heat, receiving concomitant medicinal products with anticholinergic activity or being subject to dehydration.
Pri predpisovanju zdravila Xeplion bolnikom, ki se lahko znajdejo v okoliščinah, ko se zviša temperatura jedra, npr. naporna telesna vadba, izpostavljenost skrajni vročini, sočasno jemanjen zdravil z antiholinergičnim delovanjem ali dehidracija, svetujemo ustrezno oskrbo.
Appropriate caution should be exercised when considering the treatment of such patients with pomalidomide, including periodic monitoring for signs or symptoms of cardiac failure.
Ko se ocenjuje možnost zdravljenja teh bolnikov s pomalidomidom, je potrebna ustrezna previdnost, vključno z rednim spremljanjem glede znakov in simptomov popuščanja srca.
Appropriate clinical monitoring is advisable in accordance with utilised antipsychotic guidelines , e.g. measuring of blood glucose at baseline, 12 weeks after starting olanzapine treatment and annually thereafter.
Priporoča se ustrezno klinično spremljanje v skladu z znanimi priporočili za antipsihotike, npr. merjenje glukoze v krvi na začetku, 12 tednov po začetku jemanja olanzeapina in nato enkrat na leto.
Appropriate clinical monitoring is advisable in accordance with utilised antipsychotic guidelines . e.g. measuring of blood glucose at baseline, 12 weeks after starting olanzapine treatment and annually thereafter.
Priporoča se ustrezno klinično spremljanje v skladu z znanimi priporočili za antipsihotike, npr. merjenje glukoze v krvi na začetku, 12 tednov po začetku jemanja olanzeapina in nato enkrat na leto.
Appropriate clinical monitoring is advisable in accordance with utilised antipsychotic guidelines e.g. measuring of blood glucose at baseline, 12 weeks after starting olanzapine treatment and annually thereafter.
Priporoča se ustrezno klinično spremljanje v skladu z znanimi priporočili za antipsihotike npr. merjenje glukoze v krvi na začetku, 12 tednov po začetku jemanja olanzapina in nato enkrat na leto.
Appropriate clinical monitoring is advisable in accordance with utilised antipsychotic guidelines e.g. measuring of blood glucose at baseline, 12 weeks after starting olanzapine treatment and annually thereafter.
Priporoča se ustrezno klinično spremljanje v skladu z znanimi priporočili za antipsihotike, npr. merjenje glukoze v krvi na začetku, 12 tednov po začetku jemanja olanzapina in nato enkrat na leto.
Appropriate clinical monitoring is advisable in accordance with utilised antipsychotic guidelines, e.g. measuring of blood glucose at baseline, 12 weeks after starting olanzapine treatment and annually thereafter.
Priporoča se ustrezno klinično spremljanje v skladu z znanimi priporočili za antipsihotike.
Appropriate clinical monitoring is advisable in accordance with utilised antipsychotic guidelines, e.g. measuring of blood glucose at baseline, 12 weeks after starting olanzapine treatment and annually thereafter. .
Priporoča se ustrezno klinično spremljanje v skladu z znanimi priporočili za antipsihotike, npr. merjenje glukoze v krvi na začetku, 12 tednov po začetku jemanja olanzeapina in nato enkrat na leto.
Appropriate clinical monitoring is recommended for patients receiving this type of medication concomitantly.
Bolnike, ki sočasno prejemajo to vrsto zdravil, je priporočljivo ustrezno klinično spremljati.
Appropriate clinical monitoring should be employed, as is reasonable, when co-administered with lumacaftor/ivacaftor.
Uporabiti je treba ustrezno CYP3A/2C8/2C9 z klinično spremljanje, kot je primerno, kadar LUM se uporablja sočasno z lumakaftorjem/ivakaftorjem.
appropriate combination of applicators
Ustrezna kombinacija pipet
Appropriate combination of pipettes
ustrezna kombinaci- ja merilnih kapalk
Appropriate combination of pipettes
ustrezna kombinacija
Appropriate combination of pipettes
ustrezna kombinacija merilnih kapalk
appropriate combination of pipettes
ustrezna velikost merilne kapalke
appropriate combination of pipettes
ustreznoštevilo merilnih kapalk
Appropriate disinfection procedures should be used following use of this live bacterial vaccine.
Po uporabi živega bakterijskega cepiva je treba izvesti ustrezne postopke razkuževanja.
Appropriate dose reduction for the starting dose of lenalidomide should be considered according to the recommendations in the current lenalidomide summary of product characteristics, for example for patients with baseline renal impairment.
V skladu z veljavnim povzetkom glavnih značilnosti lenalidomida je treba razmisliti o ustreznem zmanjšanju odmerka lenalidomida, na primer pri bolnikih z izhodiščno okvaro ledvic.
Appropriate dose selection and dosing interval
Izbira ustreznega odmerka in časovnega presledka med odmerjanji.
Appropriate doses for hormonal contraceptives (oral or other forms of application) other than DMPA in combination with nevirapine have not been established with respect to safety and efficacy.
Varnost in učinkovitost ustreznih odmerkov hormonskih kontraceptivov (za peroralno jemanje ali druge načine uporabe) v kombinaciji z nevirapinom, razen DMPA, nista raziskani.
Appropriate evaluation and monitoring of serum bicarbonate levels should be carried out in this population (see section 4.4 - Metabolic acidosis for full warning; see section 4.8 for incidence of low bicarbonate).
Pri tej populaciji je treba ustrezno oceniti in spremljati ravni bikarbonata v serumu (za vsa opozorila glejte poglavje 4.4 – Metabolna acidoza; glejte poglavje 4.8 za incidenco nizke ravni bikarbonata).
Appropriate infusion diluents include: sodium chloride 9 mg/mL (0.9%) solution for injection, dextrose 50 mg/mL (5%) solution for injection, sodium chloride 4.5 mg/mL and dextrose 25 mg/mL solution for injection (0.45% sodium chloride and 2.5% dextrose) or Lactated Ringer’s solution.
Ustrezni vehikli za infuzijo so: 0,9 % (9 mg/ml) raztopina natrijevega klorida za injiciranje, 5 % (50 mg/ml) raztopina glukoze za injiciranje, raztopina 4,5 mg/ml natrijevega klorida in 25 mg/ml glukoze za injiciranje (0,45 % natrijevega klorida in 2,5 % glukoze) ali raztopina Ringerjevega laktata.
Appropriate infusion solutions include: dextrose 50 mg/ml (5%) solution for injection, sodium chloride 9 mg/ml (0.9%) solution for injection or lactated Ringer’s solution for injection.
Primerne raztopine za infundiranje so med drugim: raztopina dekstroze 50 mg/ml (5 %) za injiciranje, raztopina natrijevega klorida 9 mg/ml (0,9 %) za injiciranje ali raztopina Ringerjevega laktata za injiciranje.
Appropriate injection technique
Ustrezne tehnike injiciranja.
Appropriate investigations (e.g. ultrasound) should therefore be performed up to four months after termination of Oncaspar therapy.
Zato je treba izvajati ustrezne preiskave (npr. ultrazvok) do 4 mesece po prenehanju zdravljenja z zdravilom Oncaspar.
Appropriate measures should be taken and discontinuation of parecoxib therapy should be considered if there is clinical evidence of deterioration in the condition of specific clinical symptoms in these patients.
Če se pri teh bolnikih pojavijo klinični znaki poslabšanja specifičnih kliničnih simptomov, je treba ustrezno ukrepati in razmisliti o prekinitvi zdravljenja s parekoksibom.
Appropriate measures should be taken by physicians to monitor for any serious skin reactions with therapy, e.g. additional patient consultations.
Zdravnik mora ustrezno ukrepati, da lahko nadzira morebitne resne kožne reakcije med terapijo, npr. z dodatnimi kontrolami bolnika.
Appropriate medical support and monitoring measures should be readily available when ibandronic acid intravenous injection is administered.
Pri dajanju intravenske injekcije zdravila Ibandronska kislina Accord mora biti na voljo ustrezna medicinska podpora in nadzor.
Appropriate medical treatment should always be readily available in case of rare anaphylactic reactions following the administration of the vaccine.
Tako kot pri vseh cepivih za injiciranje je, zaradi možnih redkih primerov anafilaksije po aplikaciji, potrebno vedno razpolagati s takojšnjim ustreznim zdravljenjem.
Appropriate monitoring and dose adjustment may be necessary for drugs that are CYP3A4 substrates and have a narrow therapeutic index (including but not limited to alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, sirolimus and tacrolimus) when co-administered with nilotinib.
Pri sočasni uporabi nilotiniba in zdravil, ki so substrati CYP3A4 in imajo nizek terapevtski indeks (med drugim alfentanil, ciklosporin, dihidroergotamin, ergotamin, fentanil, sirolimus in takrolimus), je potrebno ustrezno spremljanje in morda prilagajanje odmerkov.
appropriate monitoring of serum digoxin levels is recommended.
priporočljivo pa je ustrezno kontrolirati koncentracijo digoksina v serumu.
Appropriate observation of patients for serotonin syndrome-like symptoms is advised.
Priporočamo ustrezno opazovanje bolnikov glede simptomov, podobnih kot pri serotoninskem sindromu.
Appropriate precautions must be taken for women of child-bearing potential (see sections 4.3, 4.4 and 4.6).
Pri ženskah v rodni dobi moramo upoštevati ustrezne varnostne ukrepe (glejte poglavja 4.3, 4.4 in 4.6).
Appropriate precautions must continue to be used.
Bolniki se morajo še naprej držati potrebnih previdnostnih ukrepov.
Appropriate preventive analgesia medicinal products must be administered.
Bolniku morate dati ustrezen analgetik.
Appropriate procedures for proper handling and disposal of cytotoxic medicines must be followed.
Upoštevati morate ustrezne postopke za pravilno ravnanje s citotoksičnimi zdravili in njihovo odstranjevanje.
Appropriate prophylaxis should be considered for patients with a previous history of, or risk factors for, gastric or duodenal ulceration, haemorrhage or perforation.
Pri bolnikih z anamnezo razjede, krvavitev ali predrtja, povezanih z želodcem ali dvanajstnikom, ali z dejavniki tveganja za te dogodke, je treba razmisliti o profilaktičnem zdravljenju.
Appropriate screening tests, i.e. tuberculin skin test and chest X-ray, should be performed in all patients (local recommendations may apply).
Pri vseh bolnikih opravite ustrezne presejalne preiskave, npr. tuberkulinski kožni test in rentgensko slikanje prsnega koša (v skladu z lokalnimi priporočili).
Appropriate supportive medicinal products should be readily available in case of severe hypersensitivity reactions.
Zaradi morebitnih hudih preobčutljivostnih reakcij moramo imeti na razpolago ustrezna podporna zdravila.
Appropriate supportive therapies should be readily available in case of a severe hypersensitivity reaction.
Ustrezna oprema za podporno zdravljenje mora biti vedno na voljo za primere hudih preobčutljivostnih reakcij.
Appropriate symptomatic treatment could be used as needed, such as mechanical compression (e.g. for severe epistaxis), surgical haemostasis with bleeding control procedures, fluid replacement and haemodynamic support, blood products (packed red cells or fresh frozen plasma, depending on associated anaemia or coagulopathy) or platelets.
Po potrebi se lahko uvede ustrezno simptomatsko zdravljenje, kot je mehanska kompresija (n.pr. v primeru hude epistakse), kirurška hemostaza s postopki za nadzor krvavitev, nadomeščanje tekočine in hemodinamska podpora, dajanje krvnih pripravkov (koncentrirani eritrociti ali sveža zamrznjena plazma, odvisno od prisotnosti anemije ali koagulopatije) ali trombocitov.
Appropriate treatment should be promptly instituted, if indicated.
Če je indicirano, je treba takoj uvesti ustrezno zdravljenje.
Appropriate vaccination (hepatitis A and B) should be considered for patients in regular/repeated receipt of plasma-derived factor IX concentrates.
Pri bolnikih, ki redno/ponavljajoče prejemajo koncentrate iz plazme pridobljenega faktorja IX bi morali razmisliti o ustrezni obliki cepljenja (hepatitis A in B).
Approved dose in patients undergoing percutaneous coronary intervention (PCI): The licensed and approved dosing regimen of Angiox is an intravenous (IV) bolus injection of 0.75 mg/kg body weight followed immediately by an intravenous infusion at 1.75 mg/kg/hour for at least the duration of the PCI.
Odobren odmerek pri bolnikih, pri katerih se bo izvedla perkutana koronarna intervencija (PCI): potrjen in odobren režim odmerjanja zdravila Angiox je injiciranje intravenskega (i.v.) bolusa 0,75 mg/kg telesne mase, ki mu takoj sledi intravenska infuzija s hitrostjo 1,75 mg/kg/h vsaj za čas PCI.
Approved food additive (E 260), CR No 2034/96
odobren aditiv za živila (E 260), CR št.
Approved food additive (E 262), CR No 2034/96
odobren aditiv za živila (E 262), CR št.
Approved food additive (E 524), CR No 2034/96
odobren aditiv za živila (E 524), CR št.
Approx 15.0 mm x 8.0 mm, white, film coated, ovaloid, biconvex beveled edge tablet debossed with 'MLR4' on one side of the tablet and plain on the other side.
Bela, približno ovalna, bikonvensna filmsko obložena tableta z zglajenim robom, dimenzij približno 15,0 mm x 8,0 mm, z vtisnjeno oznako "MLR4" na eni strani in brez oznake na drugi strani.
Approx 18.8 mm x 10.0 mm, white, film coated, ovaloid, biconvex beveled edge tablet debossed with 'MLR3' on one side of the tablet and plain on the other side.
Bela, približno ovalna, bikonvensna filmsko obložena z zglajenim robom, dimenzij približno 18,8 mm x 10,0 mm, z vtisnjeno oznako "MLR3" na eni strani in brez oznake na drugi strani.
Approximate guidelines for initial, pre-meal EXUBERA doses, based on patient body weight, are indicated in Table 1:
Okvirne smernice za začetne odmerke zdravila EXUBERA, aplicirane pred obroki, na podlagi bolnikove telesne mase, kaže preglednica 1:
Approximate IU Dose
približni odmerek (i.e.)
Approximate tablet dimensions 13.1 mm x 5.2 mm
Tablete so velike približno 13,1 mm x 5,2 mm.
Approximately 1% of tenofovir disoproxil fumarate-treated adult patients discontinued treatment due to the gastrointestinal events.
Približno 1% odraslih bolnikov, zdravljenih z dizoproksiltenofovirijevim fumaratom je zdravljenje prekinilo zaradi neželenih učinkov v prebavnem traktu.
Approximately 1% of tenofovir disoproxil fumarate-treated adult patients discontinued treatment due to the gastrointestinal events.
Približno 1% odraslih bolnikov, zdravljenih z dizoproksiltenofovirijevim fumaratom, je zdravljenje prekinilo zaradi neželenih učinkov v prebavnem traktu.
Approximately 1-10% of individuals of Caucasian descent, 5-30% of Black African descent, 12-40% of Arab descent and 1% of Asian descent exhibit increased metabolic activity for CYP2D6 substrates and are classified as Ultra-rapid Metabolizer (UMs).
Približno 1–10 % posameznikov kavkazijskega porekla, 5–30 % posameznikov afriškega črnega porekla, 12–40 % posameznikov arabskega porekla in 1 % posameznikov azijskega porekla izkazuje povišano presnovno dejavnost za substrate CYP2D6, zato so označeni kot osebe z izjemno hitro presnovo.
Approximately 10 weeks after discontinuation of prolonged-release exenatide therapy, mean plasma exenatide concentrations fell below minimal detectable concentrations.
Približno 10 tednov po prenehanju zdravljenja z eksenatidom v obliki s podaljšanim sproščanjem srednja vrednost plazemske koncentracije eksenatida pade pod minimalno merljivo koncentracijo.
Approximately 10% of patients (10.4% and 9.8% of patients treated with the placebo/FOLFIRI and ZALTRAP/FOLFIRI regimens, respectively) received prior oxaliplatin-based adjuvant chemotherapy and progressed on or within 6 months of completion of adjuvant chemotherapy.
Približno 10 % bolnikov (10,4 % prejemnikov sheme placebo/FOLFIRI in 9,8 % prejemnikov sheme ZALTRAP/FOLFIRI) je predhodno prejemalo adjuvantno kemoterapijo na osnovi oksaliplatina, bolezen pa jim je napredovala med adjuvantno kemoterapijo ali v 6 mesecih po njenem koncu.
Approximately 10% of the total inhaled aztreonamdose is excreted in the urine as unchanged drug, as compared to 60-65% following intravenous administration of aztreonam for injection.
Približno 10% celokupnega odmerka inhaliranega aztreonama se izloči v urinu v obliki nespremenjenega zdravila, v primerjavi s 60–65% po intravenskem dajanju aztreonama za injiciranje.
Approximately 10-20% is excreted in urine.
Približno 10–20 % odmerka se izloča z urinom.
Approximately 10–20% is excreted in urine.
Približno 10-20 % odmerka se izloča z urinom.
Approximately 12 % of children treated with interferon alfa-2b and ribavirin combination therapy developed increase in thyroid stimulating hormone (TSH).
Pri približno 12 % otrok, zdravljenih s kombinirano terapijo z interferonom alfa-2b in ribavirinom, se je pojavilo povečanje vrednosti tirotropnega hormona (TSH).